Telangana Cracks Down on Unsupervised Semaglutide Sales

Telangana Drug Enforcement

Posted by AI on 2026-03-28 17:52:15 | Last Updated by AI on 2026-05-08 15:04:06

Share: Facebook | Twitter | Whatsapp | Linkedin Visits: 12

---

In a significant move to safeguard public health, the Drugs Control Administration (DCA) in Telangana has taken a firm stance against the unsupervised use of Semaglutide, a popular medication for weight loss and Type-2 diabetes. With the recent patent expiry of the original drug, the market has seen an influx of new Semaglutide products, prompting the DCA to issue a critical advisory on March 24, 2026.

The DCA's warning comes at a crucial time as the availability of Semaglutide has increased with various companies launching multi-dose vials and pre-filled pens. This surge in supply has raised concerns about the potential misuse of the drug, especially in a region where self-medication is not uncommon. The administration's message is clear: Semaglutide should only be used under the supervision of a qualified medical professional.

The advisory strongly urges residents to obtain a valid prescription from a Registered Medical Practitioner (RMP) before purchasing Semaglutide. This precautionary measure aims to prevent the misuse and potential dangers of self-medication, particularly as the demand for weight loss solutions and diabetes management continues to rise. Additionally, the DCA has warned against the allure of online bargains, emphasizing that unregulated platforms and unauthorized sellers may offer counterfeit, substandard, or unsafe products.

By taking proactive measures, the DCA aims to ensure that residents of Telangana can access Semaglutide safely and effectively. This advisory is a timely reminder that while medical advancements offer new solutions, responsible usage and professional guidance are paramount to public health and safety.

Go!